Advancing Mycoplasma Testing : Viability-Indicating NAT

[Article Title]

Reliable mycoplasma testing is critical for biopharmaceutical quality control. While DNA-targeting nucleic acid amplification techniques (DNA-NAT) provide rapid and sensitive detection, residual mycoplasma DNA from non-viable contaminants may generate signals unrelated to viable organisms. To address this challenge, CellSafe developed an RNA-targeting nucleic acid amplification technique (RNA-NAT), demonstrating sensitive detection down to 1 CFU/mL while minimizing interference from non-viable mycoplasma DNA. In this study from CellSafe, learn how RNA-NAT can advance mycoplasma testing by combining high analytical sensitivity with viability-indicating detection for biopharmaceutical quality control.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.

    Yes, I would like to receive updates from CellSafe about products, services, and other information relevant to my interests. I understand that I can unsubscribe at any time. For details on how CellSafe handles personal information, please refer to our Privacy Policy.